Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal



Page Path
HOME > Search
11 "Hak Yeon Bae"
Article category
Publication year
Funded articles
Original Article
Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin
Jong Ho Kim, Sang Soo Kim, Hong Sun Baek, In Kyu Lee, Dong Jin Chung, Ho Sang Sohn, Hak Yeon Bae, Mi Kyung Kim, Jeong Hyun Park, Young Sik Choi, Young Il Kim, Jong Ryeal Hahm, Chang Won Lee, Sung Rae Jo, Mi Kyung Park, Kwang Jae Lee, In Joo Kim
Diabetes Metab J. 2016;40(3):230-239.   Published online April 5, 2016
  • 5,523 View
  • 48 Download
  • 13 Web of Science
  • 13 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   

We compared the efficacies of vildagliptin (50 mg twice daily) relative to pioglitazone (15 mg once daily) as an add-on treatment to metformin for reducing glycosylated hemoglobin (HbA1c) levels in Korean patients with type 2 diabetes.


The present study was a multicenter, randomized, active-controlled investigation comparing the effects of vildagliptin and pioglitazone in Korean patients receiving a stable dose of metformin but exhibiting inadequate glycemic control. Each patient underwent a 16-week treatment period with either vildagliptin or pioglitazone as an add-on treatment to metformin.


The mean changes in HbA1c levels from baseline were –0.94% in the vildagliptin group and –0.6% in the pioglitazone group and the difference between the treatments was below the non-inferiority margin of 0.3%. The mean changes in postprandial plasma glucose (PPG) levels were –60.2 mg/dL in the vildagliptin group and –38.2 mg/dL in the pioglitazone group and these values significantly differed (P=0.040). There were significant decreases in the levels of total, low density lipoprotein, high density lipoprotein (HDL), and non-HDL cholesterol in the vildagliptin group but increases in the pioglitazone group. The mean change in body weight was –0.07 kg in the vildagliptin group and 0.69 kg in the pioglitazone group, which were also significantly different (P=0.002).


As an add-on to metformin, the efficacy of vildagliptin for the improvement of glycemic control is not inferior to that of pioglitazone in Korean patients with type 2 diabetes. In addition, add-on treatment with vildagliptin had beneficial effects on PPG levels, lipid profiles, and body weight compared to pioglitazone.


Citations to this article as recorded by  
  • Factors contributing to the adverse drug reactions associated with the dipeptidyl peptidase-4 (DPP-4) inhibitors: A scoping review
    Swetha R. Reghunath, Muhammed Rashid, Viji Pulikkel Chandran, Girish Thunga, K.N. Shivashankar, Leelavathi D. Acharya
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(7): 102790.     CrossRef
  • Efficacy and safety of evogliptin in patients with type 2 diabetes and non‐alcoholic fatty liver disease: A multicentre, double‐blind, randomized, comparative trial
    Eugene Han, Ji Hye Huh, Eun Y. Lee, Ji C. Bae, Sung W. Chun, Sung H. Yu, Soo H. Kwak, Kyong S. Park, Byung‐Wan Lee
    Diabetes, Obesity and Metabolism.2022; 24(4): 752.     CrossRef
  • A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study
    Soree Ryang, Sang Soo Kim, Ji Cheol Bae, Ji Min Han, Su Kyoung Kwon, Young Il Kim, Il Seong Nam‐Goong, Eun Sook Kim, Mi‐kyung Kim, Chang Won Lee, Soyeon Yoo, Gwanpyo Koh, Min Jeong Kwon, Jeong Hyun Park, In Joo Kim
    Diabetes, Obesity and Metabolism.2022; 24(9): 1800.     CrossRef
  • The rs12617336 and rs17574 Dipeptidyl Peptidase-4 Polymorphisms Are Associated With Hypoalphalipoproteinemia and Dipeptidyl Peptidase-4 Serum Levels: A Case-Control Study of the Genetics of Atherosclerotic Disease (GEA) Cohort
    Gilberto Vargas-Alarcón, María del Carmen González-Salazar, Christian Vázquez-Vázquez, Adrián Hernández-Díaz Couder, Fausto Sánchez-Muñoz, Juan Reyes-Barrera, Sergio A. Criales-Vera, Marco Sánchez-Guerra, Citlalli Osorio-Yáñez, Rosalinda Posadas-Sánchez
    Frontiers in Genetics.2021;[Epub]     CrossRef
  • Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials
    A.J. Scheen
    Diabetes & Metabolism.2020; 46(3): 186.     CrossRef
  • Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus
    Min Kyong Moon
    The Journal of Korean Diabetes.2018; 19(1): 23.     CrossRef
  • Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea
    Kyoung Hwa Ha, Bongseong Kim, Hae Sol Shin, Jinhee Lee, Hansol Choi, Hyeon Chang Kim, Dae Jung Kim
    Korean Circulation Journal.2018; 48(5): 395.     CrossRef
  • Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial
    Bancha Satirapoj, Khanin Watanakijthavonkul, Ouppatham Supasyndh, Stephen L Atkin
    PLOS ONE.2018; 13(10): e0206722.     CrossRef
  • Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus
    Min Kyong Moon, Kyu Yeon Hur, Seung-Hyun Ko, Seok-O Park, Byung-Wan Lee, Jin Hwa Kim, Sang Youl Rhee, Hyun Jin Kim, Kyung Mook Choi, Nan-Hee Kim
    The Korean Journal of Internal Medicine.2017; 32(6): 974.     CrossRef
  • Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus
    Min Kyong Moon, Kyu-Yeon Hur, Seung-Hyun Ko, Seok-O Park, Byung-Wan Lee, Jin Hwa Kim, Sang Youl Rhee, Hyun Jin Kim, Kyung Mook Choi, Nan-Hee Kim
    Diabetes & Metabolism Journal.2017; 41(5): 357.     CrossRef
  • Efficacy and safety of adding evogliptin versus sitagliptin for metformin‐treated patients with type 2 diabetes: A 24‐week randomized, controlled trial with open label extension
    Sang‐Mo Hong, Cheol‐Young Park, Dong‐Min Hwang, Kyung Ah Han, Chang Beom Lee, Choon Hee Chung, Kun‐Ho Yoon, Ji‐Oh Mok, Kyong Soo Park, Sung‐Woo Park
    Diabetes, Obesity and Metabolism.2017; 19(5): 654.     CrossRef
  • Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association
    Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
    The Korean Journal of Internal Medicine.2017; 32(6): 947.     CrossRef
  • Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association
    Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
    Diabetes & Metabolism Journal.2017; 41(5): 337.     CrossRef
Response: Clinical Marker of Platelet Hyperreactivity in Diabetes Mellitus (Diabetes Metab J 2013;37:423-8)
Jin Hwa Kim, Hak Yeon Bae, Sang Yong Kim
Diabetes Metab J. 2014;38(2):160-161.   Published online April 18, 2014
  • 3,371 View
  • 30 Download
  • 5 Web of Science
  • 5 Crossref


Citations to this article as recorded by  
  • The unique association between the level of plateletcrit and the prevalence of diabetic kidney disease: a cross-sectional study
    Shuwu Wei, Xinyu Pan, Yao Xiao, Ruishuang Chen, Junping Wei
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Impact of Uncontrolled Diabetes Mellitus on Blood Cells Indices and Plasma Components in Patients Without Nephropathy
    Hisham Ali Waggiallah, Hala Elsir Khair, Rania Saad Suliman, Humood Al Shmrany, Elturabi Elsayed Elkhider, Mudathir Mohamed Ahmed Eltayeb, Nermen Abdelftah Mohamed Ma, Yousif Mohammed Elmosaad
    Pakistan Journal of Biological Sciences.2023; 26(5): 279.     CrossRef
  • Effects of statin therapy on mean platelet volume in patients with risk of cardiovascular diseases: a systematic review and meta-analysis
    Shuaifei Ji, Babo Zhang, Xianda Wang, Heng Shi, Lixin Yu, Xiaocheng Wang
    Bioscience Reports.2019;[Epub]     CrossRef
  • The relationship between mean platelet volume and diabetic retinopathy: a systematic review and meta-analysis
    ShuaiFei Ji, Jie Zhang, XiuDe Fan, XiQiang Wang, XiaoNa Ning, BaBo Zhang, Heng Shi, Hong Yan
    Diabetology & Metabolic Syndrome.2019;[Epub]     CrossRef
  • Platelets volume indexes and cardiovascular risk factors
    Thaís Resende Batista, Roberta Carvalho de Figueiredo, Danyelle Romana Alves Rios
    Revista da Associação Médica Brasileira.2018; 64(6): 554.     CrossRef
Clinical Marker of Platelet Hyperreactivity in Diabetes Mellitus
Jin Hwa Kim, Hak Yeon Bae, Sang Yong Kim
Diabetes Metab J. 2013;37(6):423-428.   Published online December 12, 2013
  • 4,801 View
  • 66 Download
  • 26 Crossref
AbstractAbstract PDFPubReader   

Atherothrombotic complications are important causes of morbidity and mortality in diabetic patients. Diabetes has been considered to be a prothrombotic status. Several factors contribute to the prothrombotic condition, such as increasing coagulation, impaired fibrinolysis, endothelial dysfunction, and platelet hyperreactivity. Among the factors that contribute to the prothrombotic status in diabetes, altered platelet function plays a crucial role. Although understanding platelet function abnormalities in diabetes still remains as a challenge, more attention should be focused on platelet function for effective management and the prediction of atherothrombotic events in diabetic patients. This review will provide an overview on the current status of knowledge of platelet function abnormalities and clinical marker of platelet hyperreactivity in patients with diabetes.


Citations to this article as recorded by  
  • Prediction of type 2 diabetes mellitus using hematological factors based on machine learning approaches: a cohort study analysis
    Amin Mansoori, Toktam Sahranavard, Zeinab Sadat Hosseini, Sara Saffar Soflaei, Negar Emrani, Eisa Nazar, Melika Gharizadeh, Zahra Khorasanchi, Sohrab Effati, Mark Ghamsary, Gordon Ferns, Habibollah Esmaily, Majid Ghayour Mobarhan
    Scientific Reports.2023;[Epub]     CrossRef
  • Platelet P2Y1 receptor exhibits constitutive G protein signaling and β-arrestin 2 recruitment
    Agnès Ribes, Cédric Garcia, Marie-Pierre Gratacap, Evi Kostenis, Laurent O. Martinez, Bernard Payrastre, Jean-Michel Sénard, Céline Galés, Véronique Pons
    BMC Biology.2023;[Epub]     CrossRef
  • Sex differences in the relationship between platelet count and type 2 diabetes risk in community‐dwelling adults: Longitudinal findings over 14 years
    Eun Kyeong Yun, In‐Ho Seo, Hye Sun Lee, So‐Young Seol, Yong‐Jae Lee
    Diabetes/Metabolism Research and Reviews.2023;[Epub]     CrossRef
  • Platelet Glycoprotein-Ib (GPIb) May Serve as a Bridge between Type 2 Diabetes Mellitus (T2DM) and Atherosclerosis, Making It a Potential Target for Antiplatelet Agents in T2DM Patients
    Muttia Amalia, Meidi Utami Puteri, Fadlina Chany Saputri, Rani Sauriasari, Bambang Widyantoro
    Life.2023; 13(7): 1473.     CrossRef
  • Effect of oral versus parenteral vitamin D3 supplementation on nuclear factor-κB and platelet aggregation in type 2 diabetic patients
    Esraa Habiba, Samia Ali, Yehia Ghanem, Ola Sharaki, Wafaa Hewedy
    Canadian Journal of Physiology and Pharmacology.2023; 101(11): 610.     CrossRef
  • Characteristics of cerebral ischemic stroke based on moyamoya disease and atherosclerosis-associated intracranial arterial stenosis
    Zhiying Chen, Xiaoqin Wu, Da Zhou, Shuling Shang, Yuchuan Ding, Xunming Ji, Ran Meng
    Neurological Sciences.2022; 43(2): 1087.     CrossRef
  • Basic Coagulation Profiles and Platelet Parameters Among Adult Type 1 and Type 2 Diabetes Patients at Dessie Referral Hospital, Northeast Ethiopia: Comparative Cross-Sectional Study
    Hussen Ebrahim, Fikir Asrie, Zegeye Getaneh
    Journal of Blood Medicine.2021; Volume 12: 33.     CrossRef
  • Magnetic fields as a potential therapy for diabetic wounds based on animal experiments and clinical trials
    Huanhuan Lv, Junyu Liu, Chenxiao Zhen, Yijia Wang, Yunpeng Wei, Weihao Ren, Peng Shang
    Cell Proliferation.2021;[Epub]     CrossRef
  • Diabetes and hypertension: Pivotal involvement of purinergic signaling
    Karine Paula Reichert, Milagros Fanny Vera Castro, Charles Elias Assmann, Nathieli Bianchin Bottari, Vanessa Valéria Miron, Andréia Cardoso, Naiara Stefanello, Vera Maria Melchiors Morsch, Maria Rosa Chitolina Schetinger
    Biomedicine & Pharmacotherapy.2021; 137: 111273.     CrossRef
  • The hemostatic parameters in pregnant women with different types of diabetes mellitus
    R. V. Kapustin, E. V. Kopteeva, O. N. Arzhanova, A. V. Tiselko, N. Е. Androsova, T. I. Oparina
    Diabetes mellitus.2021; 24(3): 251.     CrossRef
  • Comparison of the progressive changes in hemogram parameters of normal glycemic and gestational diabetic patients throughout the first two trimesters and predictive ability of these indices for gestational diabetes mellitus
    Pelin AYTAN, Seyran BOZKURT BABUŞ, Özde SAKARYA, Revan Sabri ÇİFTÇİ, Kasım AKAY, Hakan AYTAN
    Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi.2020; 17(4): 533.     CrossRef
  • A Pilot Study on the Effect of Anti-Thrombopoietin Antibody on Platelet Count in Patients with Type 2 Diabetes
    Takuya Fukuda, Masahide Hamaguchi, Takafumi Osaka, Yoshitaka Hashimoto, Emi Ushigome, Mai Asano, Masahiro Yamazaki, Eriko Fukuda, Kei Yamaguchi, Koji Ogawa, Naoki Goshima, Michiaki Fukui
    Molecules.2020; 25(7): 1667.     CrossRef
  • Patient with diabetes after acute coronary event. How to improve forecast?
    O. L. Barbarash
    Medical alphabet.2019; 1(3): 6.     CrossRef
  • Enhanced Platelet Sensitivity to IGF-1 in Patients with Type 2 Diabetes Mellitus
    N. Gligorijevic, D. Robajac, O. Nedic
    Biochemistry (Moscow).2019; 84(10): 1213.     CrossRef
  • Comprehensive Quality Control of the Regenerative Therapy Using Platelet Concentrates: The Current Situation and Prospects in Japan
    Tomoyuki Kawase, Kazuhiro Okuda
    BioMed Research International.2018; 2018: 1.     CrossRef
  • Changes in platelet morphology indices in relation to duration of disease and glycemic control in children with type 1 diabetes mellitus
    Vybhav Venkatesh, Rakesh Kumar, Dinesh Kumar Varma, Prateek Bhatia, Jaivinder Yadav, Devi Dayal
    Journal of Diabetes and its Complications.2018; 32(9): 833.     CrossRef
  • Quantifying Platelet Margination in Diabetic Blood Flow
    Hung-Yu Chang, Alireza Yazdani, Xuejin Li, Konstantinos A.A. Douglas, Christos S. Mantzoros, George Em Karniadakis
    Biophysical Journal.2018; 115(7): 1371.     CrossRef
  • Redox Proteomics and Platelet Activation: Understanding the Redox Proteome to Improve Platelet Quality for Transfusion
    Giona Sonego, Mélanie Abonnenc, Jean-Daniel Tissot, Michel Prudent, Niels Lion
    International Journal of Molecular Sciences.2017; 18(2): 387.     CrossRef
  • Farnesoid X Receptor and Liver X Receptor Ligands Initiate Formation of Coated Platelets
    Amanda J. Unsworth, Alexander P. Bye, Dionne S. Tannetta, Michael J.R. Desborough, Neline Kriek, Tanya Sage, Harriet E. Allan, Marilena Crescente, Parveen Yaqoob, Timothy D. Warner, Chris I. Jones, Jonathan M. Gibbins
    Arteriosclerosis, Thrombosis, and Vascular Biology.2017; 37(8): 1482.     CrossRef
  • Aspirin in the prevention of cardiovascular events in patients with diabetes
    David S. H. Bell
    Postgraduate Medicine.2016; 128(2): 180.     CrossRef
    I.А. Palagina, M.Y. Kudria, О.S. Lаlymеnkо
    Fiziolohichnyĭ zhurnal.2016; 62(6): 34.     CrossRef
  • Influence of genetic variations in platelet glycoproteins and eNOS in the development of arterial ischaemia of lower limbs in type 2 diabetes mellitus patients
    Virginia Carvalhais, Ema Ruivães, Luis Bernardo Pina-Cabral, Bárbara Mesquita, Flávio Oliveira, Maria Céu Monteiro, Maria Begoña Criado
    The Foot.2016; 29: 42.     CrossRef
  • Circulating endothelial progenitor cells and angiogenic factors in diabetes complicated diabetic foot and without foot complications
    Arleta Kulwas, Ewelina Drela, Wiesław Jundziłł, Barbara Góralczyk, Barbara Ruszkowska-Ciastek, Danuta Rość
    Journal of Diabetes and its Complications.2015; 29(5): 686.     CrossRef
  • Cerebrovascular diseases: perspectives of pathogenetic metabolic haemangiocorrective treatment
    M. M. Tanashyan, O. V. Lagoda, K. V. Antonova
    Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2015; 115(9): 70.     CrossRef
  • Letter: Clinical Marker of Platelet Hyperreactivity in Diabetes Mellitus (Diabetes Metab J2013;37:423-8)
    Cengiz Beyan, Esin Beyan
    Diabetes & Metabolism Journal.2014; 38(2): 158.     CrossRef
  • Response: Clinical Marker of Platelet Hyperreactivity in Diabetes Mellitus (Diabetes Metab J2013;37:423-8)
    Jin Hwa Kim, Hak Yeon Bae, Sang Yong Kim
    Diabetes & Metabolism Journal.2014; 38(2): 160.     CrossRef
Original Articles
Association of Hemoglobin A1c with Cardiovascular Disease Risk Factors and Metabolic Syndrome in Nondiabetic Adults.
Jin Hwa Kim, So Ra Choi, Jae Rok Lee, Ji Hye Shin, Sang Jun Lee, Mi Ah Han, Jong Park, Hak Yeon Bae, Sang Yong Kim
Korean Diabetes J. 2008;32(5):435-444.   Published online October 1, 2008
  • 2,638 View
  • 22 Download
  • 6 Crossref
AbstractAbstract PDF
Glycosylated hemoglobin (HbA1c) is a useful index of mean blood glucose concentrations over the preceding 2 to 3 months. Elevated HbA1c levels (> 7%) are associated with a higher incidence of microvascular and macrovascular complications in patients with diabetes mellitus. However, the relationship between HbA1c and cardiovascualr disease risk in nondiabetic adults has been unclear. The aim of this study is to estimate the association of HbA1c with cardiovascular disease risk factors and metabolic syndrome in nondiabetic adults. METHODS: The subjects of this study included 533 adults (180 males and 353 females) aged 20~70 years (mean age: 46.9 +/- 10.12 years) without previously diagnosed diabetes who lived in Kangyang country. We examined baseline HbA1c levels and cardiovascular risk factors. Metabolic syndrome was defined based on International Diabetes Federation guidelines. RESULTS: The prevalence of metabolic syndrome significantly increased as HbA1c increased. HbA1c revealed a significant correlation with age (r = 0.258, P < 0.001), BMI (r = 0.152, P < 0.001), waist circumference (r = 0.252, P < 0.001), fasting plasma glucose (r = 0.319, P < 0.001), systolic (r = 0.100, P = 0.021), diastolic (r = 0.115, P = 0.008) blood pressure, total cholesterol (r = 0.232, P < 0.001), triglyceride (r = 0.156, P < 0.001), LDL cholesterol (r = 0.216, P < 0.001), and HDL cholesterol (r = -0.167, P < 0.001). Multiple regression analysis showed that HbA1c had a association with age, fasting plasma glucose, and dyslipidemia. The receiver operating characterstics (ROC) curve analysis determined HbA1c of 5.35% to yield optimal sensitivity and specificity corresponding to the presence of metabolic syndrome. CONCLUSION: The HbA1c level is correlated with cardiovascular risk factors and prevalence of metabolic syndrome in nondiabetic adults.


Citations to this article as recorded by  
  • Association of Glycated Proteins with Inflammatory Proteins and Periodontal Disease Parameters
    Jeneen Panezai, Mohammad Altamash, Per-Erik Engstrӧm, Anders Larsson
    Journal of Diabetes Research.2020; 2020: 1.     CrossRef
  • The Impact of Health Behaviors of Male Workers without Diabetes on HbA1c
    Ji-Yun Park, Keon-Yeop Kim, Su-Jin Lee
    Journal of Health Informatics and Statistics.2018; 43(4): 344.     CrossRef
  • Impact of initial glycosylated hemoglobin level on cardiovascular outcomes in prediabetic patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
    Donghun Shin, Jinhee Ahn, Kwang Soo Cha, Jin Sup Park, Jun-Hyok Oh, Hye-Won Lee, Ju-Yong Hong, Bo-Won Kim, Taek Jong Hong
    Coronary Artery Disease.2016; 27(1): 40.     CrossRef
  • HbA1c Levels Are Associated with Chronic Kidney Disease in a Non-Diabetic Adult Population: A Nationwide Survey (KNHANES 2011–2013)
    Seok Hui Kang, Da Jung Jung, Eun Woo Choi, Kyu Hyang Cho, Jong Won Park, Jun Young Do, Sheng-Nan Lu
    PLOS ONE.2015; 10(12): e0145827.     CrossRef
  • Usefulness of Glycated Hemoglobin as Diagnostic Criteria for Metabolic Syndrome
    Sang Hyun Park, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee
    Journal of Korean Medical Science.2012; 27(9): 1057.     CrossRef
  • Relationship between inflammation biomarkers, antioxidant vitamins, and bone mineral density in patients with metabolic syndrome
    Yesong Lee, Misung Kim, Kyungsuk Choi, Juyong Kim, Wookyung Bae, Sohye Kim, Cheongmin Sohn
    Nutrition Research and Practice.2011; 5(2): 150.     CrossRef
Evaluation of Fasting Plasma Glucose as a Screening for Diabetes Mellitus in Middle-aged Adults of Naju Country.
Jin Hwa Kim, Mi Ah Han, Chol Jin Park, Il Goo Park, Ji Hye Shin, Sang Yong Kim, So Yeon Ryu, Hak Yeon Bae
Korean Diabetes J. 2008;32(4):328-337.   Published online August 1, 2008
  • 2,683 View
  • 23 Download
  • 5 Crossref
AbstractAbstract PDF
The criteria for the diagnosis of diabetes mellitus have been modified by the American Diabetes Association (ADA) in 1997. The ADA proposed that the diagnosis of diabetes be defined by a fasting plasma glucose (FPG) of 7.0 mmol/L. Disagreement has been reported between criteria based on FPG and postchallenge 2-h plasma glucose (2-h PG). The aim of the present study is to assess the FPG criteria as the diagnostic screening test for diabetes in Korean middle-aged adults in comparison to the 2-h PG criteria. METHODS: Randomly selected 1,731 subjects (679 men and 1,052 women) aged 40~70 years (mean age: 58.4 +/- 7.89 years) without previously diagnosed diabetes completed 75 g oral glucose tolerance test (OGTT). We assessed the prevalence of diabetes mellitus and the level of agreement (kappa statistics) according to the different diagnostic glucose categories. RESULTS: The frequency of newly diagnosed diabetes was 2.7% (n = 51) using the FPG criteria only; 6.4% (n = 120) using the 2-h PG criteria only; and 6.9% (n = 130) using concentrations of > or = 7.0 mmol/L for FPG or > or = 11.1 mmol/L for 2-h PG. Of the 120 subjects with diabetes by the 2-h PG criteria, 65.8% (n = 79) were not diagnosed with diabetes according to FPG concentration. The level of agreement between two diagnostic criteria was low (kappa = 0.268). The receiver operating characterstic (ROC) curve analysis determined FPG of 5.6 mmol/L to yield optimal sensitivity and specificity corresponding to 2-h PG 11.1 mmol/L. CONCLUSION: The findings in this study demonstrate that the discordance between the FPG and 2-h PG criteria in the diagnosis of diabetes in Korean middle-aged adults is large. We suggest that IFG group (FPG 5.6~6.9 mmol/L) were performed 75 g OGTT for diagnosing diabetes mellitus in Korean middle-aged adults.


Citations to this article as recorded by  
  • The Distribution and Characteristics of Abnormal Findings Regarding Fasting Plasma Glucose and HbA1c - Based on Adults Except for Known Diabetes
    Seyoung Kwon, Youngak Na
    The Korean Journal of Clinical Laboratory Science.2017; 49(3): 239.     CrossRef
  • Gender differences in metabolic syndrome components among the Korean 66-year-old population with metabolic syndrome
    Sangjin Lee, Young Ko, Chanyeong Kwak, Eun-shil Yim
    BMC Geriatrics.2016;[Epub]     CrossRef
  • 2011 Clinical Practice Guidelines for Type 2 Diabetes in Korea
    Seung-Hyun Ko, Sung-Rea Kim, Dong-Joon Kim, Seung-Joon Oh, Hye-Jin Lee, Kang-Hee Shim, Mi-Hye Woo, Jun-Young Kim, Nan-Hee Kim, Jae-Taik Kim, Chong Hwa Kim, Hae Jin Kim, In-Kyung Jeong, Eun-Kyung Hong, Jae-Hyoung Cho, Ji-Oh Mok, Kun-Ho Yoon
    Diabetes & Metabolism Journal.2011; 35(5): 431.     CrossRef
  • Associated Factors of Impaired Fasting Glucose in Some Korean Rural Adults
    Hye Eun Yun, Mi-ah Han, Ki Soon Kim, Jong Park, Myeng Guen Kang, So Yeon Ryu
    Journal of Preventive Medicine and Public Health.2010; 43(4): 309.     CrossRef
  • Comparing Survival Functions with Doubly Interval-Censored Data: An Application to Diabetes Surveyed by Korean Cancer Prevention Study
    Sun-Ha Jee, Chung-Mo Nam, Jin-Heum Kim
    Korean Journal of Applied Statistics.2009; 22(3): 595.     CrossRef
Effects of Caloric Restriction on the Expression of PGC-1 and PPARs mRNA in Liver of Otsuka Long-Evans Tokushima Fatty Rats.
Sang Yong Kim, Jin Hwa Kim, Hak Yeon Bae, Byoung Rai Lee
Korean Diabetes J. 2006;30(3):161-169.   Published online May 1, 2006
  • 1,880 View
  • 20 Download
AbstractAbstract PDF
Gluconeogenesis is strongly stimulated during fasting and is aberrantly activated in diabetes mellitus. PPARgamma-coactivator 1 (PGC-1) and Peroxisome proliferator -activated receptors (PPARs) costimulate the expression of key enzymes of gluconeogenetic pathway. This study was performed to evaluate the response to dietary caloric restriction (CR) on the PPARs and PGC-1 expression in liver of diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats. METHODS: Diabetic OLETF rats (male, 24 weeks) and Long-Evans Tokushima Otsuka (LETO) rats (male, 24 weeks) were used in this study. Liver PPARs and PGC-1 mRNA, and blood glucose levels were investigated at 1, 2, and 3 weeks after the beginning of 30% CR. PPARs and PGC-1 mRNA were determined by RT-PCR and blood glucose levels were measured by spectrophotometric assay. RESULTS: The liver PGC-1 mRNA expressions were increased to 19% in non-diabetic LETO rats but significant change was not observed in diabetic OLETF rats by 30% CR. The liver PPARgamma mRNA expressions were not changed in non-diabetic LETO rats but increased to 23% in diabetic OLETF rats by 30% CR. The difference of PPARalpha and PPARbeta mRNA expressions in liver of OLETF and LETO rats were not observed. CONCLUSION: The liver PPARgamma and PGC-1 expression response to CR are altered in OLETF rats compared to in LETO rats. These findings suggested that PPARgamma and PGC-1 expression control system altered in diabetic OLETF rat liver and altered PPARgamma and PCG-1 expression may some roles on the aberrantly activated gluconeogenesis in diabetes mellitus.
Effects of Gutathione on Cyclosporine A-induced Cyotoxicity in Cultured Rat Insulinoma (RIN5mF) Cells.
Dong Hyun Choi, Byoung Rai Lee, Dai Yong Jang, Jong O Kim, Byung Soo Kim, Ki Young Chung, Tae Young Lim, Byung Chul Shin, Hak Yeon Bae
Korean Diabetes J. 2002;26(1):58-64.   Published online February 1, 2002
  • 1,011 View
  • 18 Download
AbstractAbstract PDF
Cyclosporin A (CsA) is a immunosuppressive agent that is most widely used in organ transplanted patients to prevent immunorejection, However, it has some side effects, including diabetes mellitus, nephrotoxicity and hypertension. The mechanism of CsA cytotoxicity is unclear but it has been suggested that reactive oxygen species are involved in the cytotoxic reactions. The purpose of this study was to determine the effects of glutathione, as a physiological antioxidant on CsA induced beta-cell toxicity. METHODS: Rat insulinoma (RINm5F) cells were incubated with culture media (RPMI1640) in the presence of CsA and/or buthionine sulfoximine (BSO), which is an inhibitor of r-glutamyl cysteine synthetase, and reduced glutathione. The viable cells were examined using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) and was determined by a spectrophotometer at a wavelength of 570 nm. RESULTS: Incubating the RINm5F cells with CsA resulted in a decrease in cell viability with increasing dose. This deceased cells viability, induced by CsA was potentiated by BSO treatment. The CsA and BSO induced cells toxicity was reduced significantly by the reduced glutathione. CONCLUSION: The results suggest that pancreatic beta-cell may be injured by CsA and glutathione may have some role in cytotoxicity.
Changes of TBARS and GGTase in Ischemia / Reflowed Kidney of Alloxan-diabetic Rat.
Jong Hoon Chung, Hak Yeon Bae, Jong Hee Cha, Jae Yoon Park, Pyoung Sim Park, Kwang Sam Koh, Byoung Rai Lee
Korean Diabetes J. 1999;23(6):777-784.   Published online January 1, 2001
  • 852 View
  • 16 Download
AbstractAbstract PDF
To investigate the influence of diabetes mellitus (DM) on ischemia/reflow injury, the contents of thiobarbituric acid reactive substance (TBARS: marker of peroxidative cell injury), and the activity of gamma-glutamyltransferase (GGTase: marker of brush border membrane injury) were measured in ischemia/reflowed kidney of diabetic rats. METHODS: Rats were divided into the 3 groups; control (C), diabetes for 2 weeks (DM2) and diabetes for 4 weeks (DM4), and DM was induced by alloxan (80 mg/kg ip). Left kidney was subjected to 30 min of ischemia and 15 min of blood reflow, and the right kidney was used as a control kidney. The activities of antioxidant enzymes and GGTase, and the contents of TBARS were determined in kidney homogenate. RESULT: Catalase activity in ischemia/reflowed kidney was decreased 20% (p<0.05) in C, 34% (p<0.01) in DM2 and 23% (p<0.01) in DM4, while the change of SOD and GSHPx activities were not observed in kidney of diabetic rats cornpared with group C. TBARS contents, when ischemia/reflow, increased by 23% in C, 19% (p<0.01) in DM2, 16% in DM4, while the activity of GGTase decreased by 40% i#n C, 54% in DM2, and 55% (p<0.01) in kidney of DM4. CONCLUSION: The TBARS contents in ischemia/ reflow kidney of diabetic group showed no change, while GGTase activity was decreased significantly when compared with control group. This study may suggested that in ischemia/reflow kidney, the peroxidative membrane lipid injury was not increased, but the brush border membrane injury was increased by DM.
The Role of Oxidized Low Density Lipoprotein in Atherogenesis.
Hak Yeon Bae
Korean Diabetes J. 1999;23(1):7-11.   Published online January 1, 2001
  • 786 View
  • 16 Download
AbstractAbstract PDF
No abstract available.
Plasma Paraoxonase Activities in Type 2 Diabetes Mellitus.
Gyoung Mu Her, Hak Yeon Bae, Byoung Rai Lee
Korean Diabetes J. 1998;22(3):403-409.   Published online January 1, 2001
  • 765 View
  • 21 Download
AbstractAbstract PDF
Human serum paraoxonase is physically associated with HDL and has been implicated in the detoxification of organophosphate and possibly in the prevention of LDL lipid peroxidation. The activities of paraoxonase and levels of HDL cholesterol were measured in the serum of individuals with type 2 diabetes mellitus in order to evaluate whether a correlation exists between these cnzyme activities and the diabetes mellitus and dliabetic complications. METHODS: Plasma samples were obtain from 60 individuals with type 2 diabetes mellitus(32 women and 28 men; mean age=55.8 yrs) and 30 individuals with healthy control(16 women and 14 men; mean age=-54.1 yrs). Paraoxonase activities were measured spectrophotometrically in 0.1IM Tris-HC1 buffer(pH= 7.4) at 25C with paraoxon as substrate(5.5mM) at 405nm. RESULTS: No significant differences of plasma paraoxonase activity between healthy control and type 2 diabetes mellitus were observed. The significant difference of plasma paraoxonase activity between healthy control and type 2 diabetes mellitus with diabetic complications such as diabetic neuropathy, diabetic retinopathy and diabetic nephropathy were observed. The difference of plasma paraoxonase activity between individuals with type 2 diabetes mellitus without diabetic complication and type 2 diabetes mellitus with diabetic complications was significant. The correlation between paraoxonase activity and HDL-cholesterol, plasma lipoproteins, HbAlc and duration of diabetes were not observed. CONCLUSION: These experimental results suggested that the plasma paraoxonase activity wasnt decreased in individuals with type 2 diabetes mellitus without diabetic complication and the decrement of plasma paraoxonase activity was might be associated with diabetic chronic complications.
The Effect of High Glucose on the Activity of Superoxide Dismutase in NIN6N8a Cells.
Hak Yeon Bae, Byoung Rai Lee, Kwang Sam Kho
Korean Diabetes J. 1998;22(3):271-289.   Published online January 1, 2001
  • 808 View
  • 17 Download
AbstractAbstract PDF
Reactive oxygen species play a role in the pathogenesis of diabetes mellitus. Hyperglycemia may cause increased production of free radicals, and peroxide formation was increased in high glucose solution. It has been demonstrated that active oxygen species induce antioxidant enzyme expression in some tissues and cells. This study was designed to investigate the effect of high glucose on the activity of superoxide dismutase(SOD) in mouse insulinoma(MIN6N8a) cells. METHODS: MIN6N8a cells were grown in RPMI1640 medium with l0% fetal bovine serum and NIH3T3 cells used as a control cells. The cells were cultured in 5.6 and 22.2 mM glucose cnntained medium. The activities of SOD, catalase and GPX were determined in crude cell extract after 7 days of culture. The levels of CuZn-SOD were also measured with ELISA using anti-CuZn-SOD antibody. RESULTS: In MIN6NSa cells, the catalase activity was very low compared with NIH3T3 cells, but there was no difference in activities of CuZn-SOD and GPX between MIN6N8a cells and NIH3T3 cells. The activity of CuZn-SOD was decreased, while Mn-SOD was increased in MIN6NSa cells cultured with high glucose(22.2 mM) medium compared with those of normoglucose(5.6 mM) medium. However, the level of CuZn-SOD in MIN6NSa cells, when measured with ELISA was high in cells of cultured with high glucose medium. The SOD activity was not effected in MIN6N8a cells cultured with insulin contained medium. CONCLUSION: These experimental result suggest that the CuZn-SOD activity was decreased in MIN6N8a cells cultured with high glucose contained medium and this effect may be resulted from the protein inactivation rather than decrement of protein level.

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer